SAS Output

22-SEP-2017 18:11

OPEN STUDIES IRB REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Disease
Site
Study Study Name Open Date Number of
Active
Institutions
Number of
Current
IRBs
 
BREAST S1007 Breast,Adj,N1,Endocrine+/-Chemo 15-JAN-11 413 205
  S1207 Brst,Adj,Endocrine+/-Everolimus 03-SEP-13 458 239
  S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 07-JUL-16 264 124
  S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 15-NOV-16 382 165
  A011106 Breast, Neoadj, ALTERNATE study 15-FEB-14 249 115
  A011401 Breast, adj, Stage II/III HER2-, weight loss 29-AUG-16 403 220
  A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 08-DEC-16 0 190
  A221405 Breast, ET interruption, Pregnancy Outcomes 15-OCT-15 0 14
  B55 Brst, Adj Olaparib for BRCA,TNBC 03-JUL-14 409 181
  E1Z11 Brst,Genetic Predictors of AIMSS 10-MAY-13 259 86
  E2112 Brst,Adv,Exemestane+/-Entinostat 02-JAN-14 289 167
  NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo 22-JAN-15 422 216
 
CCD S1415CD TrACER CSF Standing Order Intervention for FN 01-SEP-16 38 31
  S1417CD Colorectal, Cost Cohort Study 13-MAY-16 199 59
  A011104 Preoperative Breast MRI 21-FEB-14 166 60
 
ERLYTX S1609 Rare Tumor, Comb Nivo/Ipi 13-JAN-17 333 142
  A071102 GBM, adj TMZ +/- Veliparib 19-SEP-14 378 168
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 06-AUG-15 248 104
  ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) 16-MAY-14 244 117
  EAY131 MATCH 12-AUG-15 441 236
 
GI S1505 Panc,Resect, Perioperative Chemo 12-OCT-15 279 116
  S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 01-SEP-16 302 143
  A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT 01-DEC-16 0 23
  EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo 29-JAN-16 0 34
  EA2142 GI NEC, Adv G3, EP vs TMZ + CAP 06-NOV-15 184 71
  N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX 13-JAN-12 0 158
  NRGGI002 Rectal, Ph II, Sensitization using TNT 12-OCT-16 289 121
  R0848 Panc, Adj, Erlotinib v ChemoRT 01-MAR-14 0 152
 
GU S1314 Blad, COXEN Neoadj. Chemo + Cyst 11-JUL-14 223 118
  S1500 pRCC,Adv, Sunitinib vs MET inhib 05-APR-16 196 87
  S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 07-FEB-17 136 61
  S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab 07-FEB-17 133 58
  A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 01-JUL-15 56 33
  EA8141 UTUC, HG, Chemo then Surg 27-JAN-15 153 75
  NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel 30-DEC-16 0 6
  R0924 Pros, NADT+WPRT vs. NADT+P&SV RT 07-JUL-11 0 163
 
LEUK S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP 01-APR-14 4 5
  S1318 ALL, Age 65+, Ph±, Blinatumomab 12-JAN-15 176 73
  E1910 BCR-ABL-neg, B ALL, Blinatumomab 23-DEC-13 167 92
  E2906 AML, Age 60+, Clo vs Dauno+Cy 24-FEB-11 152 80
  NHLBIMDS LEUK, National MDS Study 05-APR-16 62 27
 
LUNG S1400 SCCA,Adv, Biomarker Master 15-JUN-14 432 223
  S1400G HRRD: Talazoparib (BMN 673) 07-FEB-17 432 222
  S1400I Non-Match: Nivo + Ipi vs Nivo 18-DEC-15 433 223
  S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab 25-MAR-15 224 92
  S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel 18-JUL-16 185 85
  8811 NSCLC, Stage III,ChemoRT+ABT-888 02-JAN-13 133 54
  A081105 ALCHEMIST1, EGFR mut, Erlotinib 02-JAN-14 0 248
  A151216 ALCHEMIST0 - screening 06-FEB-14 455 250
  C30610 SCLC, Thoracic RT 21-MAR-08 240 116
  E4512 ALCHEMIST2, ALK mut, Crizotinib 18-AUG-14 458 257
  EA5142 ALCHEMIST3, Non-match, Nivolumab 16-MAY-16 454 244
  NRGCC003 SCLC, PCI or HA-PCI 07-DEC-15 322 143
  R1306 NSCLC,Adv,ALK/EGFR,TargetAgents 04-NOV-13 162 70
 
LYMPH S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob 10-AUG-17 0 16
  A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo 15-JUL-16 131 57
 
MELAN S1320 Adv, BRAF mut, Inter v Contin 22-JUL-14 246 110
  S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 15-OCT-15 392 172
  S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) 20-OCT-16 73 31
  S1616 MELAN,, Adv, Ipilimumab ± Nivolumab 17-JUL-17 0 34
  EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 15-DEC-15 336 143
  EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim 01-MAR-16 299 123
 
MMYEL E1A11 MM, frontline, BLD vs CLD 22-NOV-13 298 130
 
OTHER A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo 02-SEP-14 53 30
  A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II 26-JAN-15 184 65
  A091305 HN, Adv, Thyroid PPAR agonist + Chemo 01-SEP-14 117 36
  A091401 Sarc, 18-JUN-15 195 77
  A091404 HN, AR+, Enzalutamide 25-SEP-15 94 40
  EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp 29-MAR-16 0 8
  EAQ152 Communication & education in tumor profiling 26-SEP-16 232 103
  G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT 12-APR-10 0 4
  G0281 Ovar, Recur/prog LG, IC chemo vs trametinib 27-FEB-14 0 82
  NRGBN001 HN, novel vs. std chemoradiation + chemo 28-AUG-15 0 109
  NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo 04-FEB-16 342 176
  NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care 06-FEB-16 320 140
  NRGHN001 Nasopharyngeal , Indiviual Tx EBV 21-APR-14 190 68
  R0724 Cervical, Chem+RT +/- Adj. Chemo 15-JAN-14 254 104
  R0920 HN, Adv, Postop IMRT ± Cetuximab 24-DEC-13 331 152
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 275 121
 
PREV S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac 01-MAR-13 305 110
  A211102 Breast, Atypia via RPFNA, Metformin v Placebo 01-FEB-15 25 10
  A211201 Breast Density, MA.32 companion 22-AUG-12 25 15
  EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis 02-SEP-16 0 8
 
SURV S1316 Compar. Effectiv. Trial for MBO 09-MAR-15 13 18
  S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol 15-SEP-17 0 5
  E1Q11 EROS: Reproductive Health in Cancer Survivors 30-SEP-15 0 36
 
SXQOL A221101 Glioma, Nuvigil/Placebo Fatigue 03-JUN-13 228 91
  A221102 Brst,AI Arthralgia,Testosterone 07-SEP-12 0 67